CBP-1008

News alerts, weekly reports and conference planners

Company:

Coherent Biopharma

Drug class:

Microtubule inhibitor, Folate receptor 1 inhibitor, TRPV6 inhibitor

FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	CBP-1008 Sensitive: C3 – Early Trials CBP-1008 Sensitive : C3	CBP-1008 Sensitive: C3 – Early Trials CBP-1008 Sensitive : C3
TRPV6 positive	Ovarian Cancer	TRPV6 positive	Ovarian Cancer	CBP-1008 Sensitive: C3 – Early Trials CBP-1008 Sensitive : C3	CBP-1008 Sensitive: C3 – Early Trials CBP-1008 Sensitive : C3
FOLR1 positive + TRPV6 positive	Ovarian Cancer	FOLR1 positive + TRPV6 positive	Ovarian Cancer	CBP-1008 Sensitive: C3 – Early Trials CBP-1008 Sensitive : C3	CBP-1008 Sensitive: C3 – Early Trials CBP-1008 Sensitive : C3

Associations
(3)